This site is intended for patients who have been prescribed Remicade (infliximab). If you are a Healthcare Professional then please visit the HCP site, or if you are a member of the public please visit our public site. This site is not a substitute for the Patient Information Leaflet (PIL). The information provided is general education information and does not take place of professional medical advice.

Starting Treatment

Before you start treatment with Remicade (infliximab), your healthcare professional will need to ask you a few questions about your health. This is to make sure you don’t have any other conditions which might stop you receiving treatment and to involve you in the decision making process.

Doing this doesn’t necessarily mean that you can’t have Remicade (infliximab), but having as much information as possible will help your healthcare professional to plan your treatment.

Also, you will be weighed and you may need to have some screening tests. These may include:

  • Tests on your blood: The healthcare professional might do some blood tests to find out whether you have any infections
  • Tests for tuberculosis (TB), which may include a chest X-ray: Some people may have been exposed to TB without knowing it. Remicade (infliximab) should not be given to people with TB, so if you have TB or your healthcare professional feels that you are at risk of TB, you may be treated with medicines for TB before you start your treatment.


Tell your healthcare professional if you have been feeling unwell before you receive your treatment.

Before starting treatment you should tell your healthcare professional if:

  • you are allergic to infliximab or to any of the other ingredients in Remicade
  • you are allergic (hypersensitive) to proteins that come from mice
  • you have received infliximab in the past
  • you have an infection
  • you are a carrier or if you have or have had hepatitis B
  • you have any heart problems, such as mild heart failure
  • you have or have ever had lymphoma (a type of blood cancer) or any other cancer
  • you have a lung disease called Chronic Obstructive Pulmonary Disease (COPD) or if you are a heavy smoker
  • you have or have ever had a problem that affects your nervous system
  • you have any abnormal skin openings (fistulae)
  • you have recently had or are due to have a vaccine
  • you are going to have any operations or dental procedure


Links to external sites

The link you have selected will take you to a third-party website. We do not review or control the content of any third-party site. We do not endorse and are not responsible for the accuracy, content, practices, or standards of any third-party sources.


  1. Kanai T et al. Korean J Intern Med 2014; 29(4): 409-15
  2. Olendzki BC et al. Nutr J 2014; 13(5): 1-7.
  3. Brown AC et al. Expert Rev. Gastroenterol. Hepatol 2011; 5(3): 411-25
  4. Pituch-Zdanowksa A et al. Prz Gastroenterol 2015; 10(3): 135-41.
  5. Oliviero F et al. Swiss Med Wkly 2015; 145: w14190.
  6. Clinton CM et al. Arthritis 2015; 2015: Article ID 708152.
  7. Narula N, Fedorak RN. Can J Gastroenterol 2008; 22 (5): 497-504
  8. Bilski J et al. BioMed Res Int 2014; Volume 2014 (Article ID 429031): 1-14.
  9. Benatti FB, Pedersen BK. Nat Rev Rheumatol 2015; 11: 86-97
  10. Nolte K et al. S Afr Fam Pract 2013; 55: 345-9
  11. Metsios GA et al. Expert Rev Clin Immunol 2015 [Epub ahead of print]
  12. Brophy S et al. Semin Arthritis Rheum 2013; 42: 619-26


For further information about Remicade (infliximab) please contact our Medical Information Department at:

Medical Information Department

Merck Sharp & Dohme (UK) Limited.

Registered Office: 120 Moorgate



United Kingdom

Tel: 01992 467272